Bristol Myers Squibb
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of BMY would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (1972) — listing | $3,149,072 38.6× | $4,564,328 38.6× |
| Year 6 (1977) | $1,757,038 23.5× | $2,542,534 23.5× |
| Year 11 (1982) | $711,437 10.6× | $1,029,140 10.6× |
| Year 16 (1987) | $341,761 5.7× | $494,617 5.7× |
| Year 21 (1992) | $209,597 4.0× | $303,416 4.0× |
| Year 26 (1997) | $124,580 2.8× | $180,736 2.8× |
| Year 31 (2002) | $101,533 2.8× | $147,279 2.8× |
| Year 36 (2007) | $62,298 2.1× | $90,560 2.1× |
| Year 41 (2012) | $30,466 1.4× | $44,340 1.4× |
| Year 46 (2017) | $17,033 1.2× | $24,786 1.2× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
New York City, United States
Popular scenarios with BMY
For illustration only — not investment advice. Past performance is not indicative of future results.